Cardiovascular diseases are the world's leading cause of death, and high blood pressure, or hypertension, affects more than 1 ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...

Before receiving a kidney transplant, patients with autosomal dominant polycystic kidney disease often undergo a nephrectomy. But there hasn’t been clear guidance on who’s a good candidate ...

The development of α7 nAChR antagonists has received only minor attention from the drug development sector. It is currently unclear whether reduced receptor activity through desensitization and ...

Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824, United States Department of Computational Mathematics, Science and Engineering, Michigan ...

Some Endothelin Receptor Antagonists (ERAs ... Drugs that inhibit the renin-angiotensin system (RAS) can cause kidney injury. Patients whose kidney function may depend in part on the activity ...

The result is "consistent with prior studies of injectable semaglutide and other GLP-1 receptor agonist," but a positive result is still a big deal, said principal investigator Darren K.

Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States ...

195 REPUBLICANS TEAMED WITH TWO DEMOCRATS TO PASS LEGISLATION BANNING PUBERTY BLOCKERS TO TRANSITION THE GENDER OF KIDS UNDER THE AGE OF 18. SOME SAY THE BILL IS DISCRIMINATORY BECAUSE IT INCLUDES ...

inhibitors and angiotensin receptor blockers (ARBs) are classes of drugs commonly prescribed for blood pressure and heart conditions. Some information about them is: ACE inhibitors end in the letters ...

The NH House passed a bill Thursday 197-167 that would ban health care professionals from administering hormone treatments or puberty blockers for the purpose of gender transition to anyone under 18.

mineralocorticoid receptor antagonists [MRAs], beta-blockers, angiotensin-converting enzyme [ACE] inhibitors, and angiotensin receptor blockers [ARBs]). They included 11,277 general cardiologists ...